Human Amniotic Epithelial Cells for Asherman's Syndrome
Primary Purpose
Asherman's Syndrome
Status
Unknown status
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
hAECs
biological amnion
Sponsored by
About this trial
This is an interventional treatment trial for Asherman's Syndrome
Eligibility Criteria
Inclusion Criteria:
- 1. Hysteroscopy examination confirms intrauterine adhesions, II -III according to the American Fertility Society (AFS) classification of uterine adhesions;
- 2. Regular Menstrual cycles and menstruation is normal before abortion or curettage;
- 3. Having a clear desire to fertility;
- 4. Normal blood coagulation, liver, heart, and kidney function, absence of HIV, Hepatitis B or C, syphilis and psychiatric pathology;
- 5. Serum β-hCG is negative;
- 6. Be willing to complete the study and sign the consent form.
Exclusion Criteria:
- 1. Having a history of malignant tumor;
- 2. Having other uterine diseases, such as, uterine fibroids, adenomyosis and uterine malformations;
- 3. Hysteroscopic adhesiolysis more than 3 times in the past;
- 4. Absence of peripheral vein access.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Experimental
Placebo Comparator
Experimental
Experimental
Experimental
Arm Label
biological amnion loaded with hAECs
biological amnion
intravenous infusion of hAECs
intrauterine infusion of hAECs
hydrogel loaded with hAECs
Arm Description
Biological amnion loaded with 100 million hAECs is placed into uterine cavity immediately after TCRA.
Biological amnion is placed into uterine cavity immediately after TCRA.
intravenous infusion of 100 million hAECs immediately after TCRA
100 million hAECs is infused into uterine cavity immediately after TCRA.
Hydrogel loaded with 100 million hAECs is infused into uterine cavity immediately after TCRA.
Outcomes
Primary Outcome Measures
Menstrual blood volume
Estimate the menstrual blood volume after surgery by the number of sanitary napkins per day and number of days, which will be compared with pre-operation.
Secondary Outcome Measures
Endometrial thickness
Measure the endometrial thickness during periovulatory period on ultrasound by the same trained medical sonographers at 3 months after surgery, compared with pre-operation.
Uterine volume
Measure the uterine volume during periovulatory period on ultrasound by the same trained medical sonographers at 3 months after surgery, compared with pre-operation.
Ongoing pregnancy rate
A ongoing pregnancy means that at the 12th week of pregnancy, ultrasound reveals that the fetus had a heart beat and the size of the fetus is in consistent with the gestational week.
Full Information
NCT ID
NCT03223454
First Posted
July 13, 2017
Last Updated
July 19, 2017
Sponsor
The Second Affiliated Hospital of Chongqing Medical University
Collaborators
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
1. Study Identification
Unique Protocol Identification Number
NCT03223454
Brief Title
Human Amniotic Epithelial Cells for Asherman's Syndrome
Official Title
Safety and Therapeutic Effect of Human Amniotic Epithelial Cells in Severe Refractory Asherman's Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
July 2017
Overall Recruitment Status
Unknown status
Study Start Date
October 2017 (Anticipated)
Primary Completion Date
September 2019 (Anticipated)
Study Completion Date
March 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Second Affiliated Hospital of Chongqing Medical University
Collaborators
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This project aims to investigate the safety and effectiveness of human amniotic epithelial cells in the treatment of the severe refractory Asherman's syndrome.
Detailed Description
Asherman's syndrome is a gynecological disorder caused by the destruction of the endometrium due to repeated or aggressive curettages and/or endometritis. As a result, there is a loss of functional endometrium in multiple areas and the uterine cavity is obliterated by intrauterine adhesions, which results in amenorrhea, hypomenorrhea, infertility and recurrent pregnancy loss. Transcervical resection of adhesion (TCRA) is the main treatment for Asherman's syndrome, so far the effect is usually poor in moderate to severe refractory cases.
Human amniotic epithelial cells (hAECs) are derived from human amniotic epithelium. hAECs retain the characteristics approximating to embryonic stem cells. Animal experiments have shown that the endometrial thickness and fertility of mice were significantly improved after intrauterine therapy with amniotic epithelial cells. To further explore the role of hAECs in Asherman's syndrome patients, this project plans to evaluate the safety of hAECs provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd., and find an effective treatment protocol.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asherman's Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
biological amnion loaded with hAECs
Arm Type
Experimental
Arm Description
Biological amnion loaded with 100 million hAECs is placed into uterine cavity immediately after TCRA.
Arm Title
biological amnion
Arm Type
Placebo Comparator
Arm Description
Biological amnion is placed into uterine cavity immediately after TCRA.
Arm Title
intravenous infusion of hAECs
Arm Type
Experimental
Arm Description
intravenous infusion of 100 million hAECs immediately after TCRA
Arm Title
intrauterine infusion of hAECs
Arm Type
Experimental
Arm Description
100 million hAECs is infused into uterine cavity immediately after TCRA.
Arm Title
hydrogel loaded with hAECs
Arm Type
Experimental
Arm Description
Hydrogel loaded with 100 million hAECs is infused into uterine cavity immediately after TCRA.
Intervention Type
Biological
Intervention Name(s)
hAECs
Intervention Description
hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
Intervention Type
Biological
Intervention Name(s)
biological amnion
Intervention Description
Biological amnion is purchased from JiangXi RuiJi BioTechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
Primary Outcome Measure Information:
Title
Menstrual blood volume
Description
Estimate the menstrual blood volume after surgery by the number of sanitary napkins per day and number of days, which will be compared with pre-operation.
Time Frame
at 3 months
Secondary Outcome Measure Information:
Title
Endometrial thickness
Description
Measure the endometrial thickness during periovulatory period on ultrasound by the same trained medical sonographers at 3 months after surgery, compared with pre-operation.
Time Frame
at 3 months
Title
Uterine volume
Description
Measure the uterine volume during periovulatory period on ultrasound by the same trained medical sonographers at 3 months after surgery, compared with pre-operation.
Time Frame
at 3 months
Title
Ongoing pregnancy rate
Description
A ongoing pregnancy means that at the 12th week of pregnancy, ultrasound reveals that the fetus had a heart beat and the size of the fetus is in consistent with the gestational week.
Time Frame
up to 24 months
10. Eligibility
Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
1. Hysteroscopy examination confirms intrauterine adhesions, II -III according to the American Fertility Society (AFS) classification of uterine adhesions;
2. Regular Menstrual cycles and menstruation is normal before abortion or curettage;
3. Having a clear desire to fertility;
4. Normal blood coagulation, liver, heart, and kidney function, absence of HIV, Hepatitis B or C, syphilis and psychiatric pathology;
5. Serum β-hCG is negative;
6. Be willing to complete the study and sign the consent form.
Exclusion Criteria:
1. Having a history of malignant tumor;
2. Having other uterine diseases, such as, uterine fibroids, adenomyosis and uterine malformations;
3. Hysteroscopic adhesiolysis more than 3 times in the past;
4. Absence of peripheral vein access.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lina Hu
Phone
86-23-63693707
Email
cqhulina@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
Chanyu Zhang
Phone
86-23-63693296
Email
1317954623@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lina Hu
Organizational Affiliation
The Second Affiliated Hospital of Chongqing Medical University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Chanyu Zhang
Organizational Affiliation
The Second Affiliated Hospital of Chongqing Medical University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Fan He
Organizational Affiliation
The Second Affiliated Hospital of Chongqing Medical University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jianguo Hu
Organizational Affiliation
The Second Affiliated Hospital of Chongqing Medical University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Heng Zou
Organizational Affiliation
The Second Affiliated Hospital of Chongqing Medical University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Huijia Chen
Organizational Affiliation
The Second Affiliated Hospital of Chongqing Medical University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
18406834
Citation
Yu D, Wong YM, Cheong Y, Xia E, Li TC. Asherman syndrome--one century later. Fertil Steril. 2008 Apr;89(4):759-79. doi: 10.1016/j.fertnstert.2008.02.096.
Results Reference
background
PubMed Identifier
18995896
Citation
Ilancheran S, Moodley Y, Manuelpillai U. Human fetal membranes: a source of stem cells for tissue regeneration and repair? Placenta. 2009 Jan;30(1):2-10. doi: 10.1016/j.placenta.2008.09.009. Epub 2008 Nov 7.
Results Reference
background
Learn more about this trial
Human Amniotic Epithelial Cells for Asherman's Syndrome
We'll reach out to this number within 24 hrs